Determinants of high cost in multiple sclerosis patients: a claims and chart review study

References

• National Multiple Sclerosis Society. Available at http://www.nationalmssociety.org/about-multiple-sclerosis [Last accessed 31 January 2014]
   Google Scholar
• Asche CV, Singer ME, Jhaveri M, et al. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm 2010;16:703-12
   PubMed Web of Science ®Google Scholar
• Frohman EM. Multiple sclerosis. Med Clin North Am 2003;87:867-8ix
   PubMed Web of Science ®Google Scholar
• Happe LE. Choosing the best treatment for multiple sclerosis: comparative effectiveness, safety, and other factors involved in disease-modifying therapy choice. Am J Manag Care 2013;?:S332-S42
   Google Scholar
• Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52
   PubMed Web of Science ®Google Scholar
• Rice CM, Cottrell D, Wilkins A, et al. Primary progressive multiple sclerosis: progress and challenges. J Neurol Neurosurg Psychiatry 2013;84:1100-6
   PubMed Web of Science ®Google Scholar
• Schafer JA, Gunderson BW, Gleason PP. Price increases and new drugs drive increased expenditures for multiple sclerosis. J Manag Care Pharm 2010;16:713-17
   PubMed Web of Science ®Google Scholar
• O’Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003;3:17
   PubMed Web of Science ®Google Scholar
• Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ 2013;16:639-47
   PubMedGoogle Scholar
• Gilden DM, Kubisiak J, Zbrozek AS. The economic burden of Medicare-eligible patients by multiple sclerosis type. Value Health 2011;14:61-9
   PubMed Web of Science ®Google Scholar
• Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-78
   PubMed Web of Science ®Google Scholar
• Kantarci O, Wingerchuk D. Epidemiology and natural history of multiple sclerosis: new insights. Curr Opin Neurol 2006;19:248-54
   PubMed Web of Science ®Google Scholar
• Gold R. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS Drugs 2011;25:37-52
   PubMed Web of Science ®Google Scholar
• Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol 2011;10:1026-34
   PubMed Web of Science ®Google Scholar
• Naci H, Fleurence R, Birt J, et al. Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics 2010;28:363-79
   PubMed Web of Science ®Google Scholar
• Margolis JM, Fowler R, Johnson BH, et al. Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study. BMC Neurol 2011;11:122
   PubMed Web of Science ®Google Scholar
• Hartung DM, Bourdette DN, Ahmed SM, et al. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail? Neurology 2015;84:2185-92
   PubMed Web of Science ®Google Scholar
• O’Connell K, Kelly SB, Fogarty E, et al. Economic costs associated with an MS relapse. Mult Scler Relat Disord 2014;3:678-83
   PubMed Web of Science ®Google Scholar
• Trish E, Joyce G, Goldman DP. Specialty drug spending trends among Medicare and Medicare Advantage enrollees, 2007–11. Health Aff (Millwood) 2014;33:2018-24
   PubMed Web of Science ®Google Scholar
• Yermakov S, Davis M, Calnan M, et al. Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis. J Med Econ 2015;18:711-20
   PubMed Web of Science ®Google Scholar
• Kamat SA, Rajagopalan K, Stephenson JJ, et al. Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional survey. Patient 2009;2:105-12
   PubMedGoogle Scholar
• Stephenson JJ, Kern DM, Agarwal SS, et al. Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study. Health Qual Life Outcomes 2012;10:155
   PubMed Web of Science ®Google Scholar
• Tan H, Yu J, Tabby D, et al. Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study. Mult Scler 2010;16:956-63
   PubMed Web of Science ®Google Scholar
• Capkun G, Lahoz R, Verdun E, et al. Expanding the use of administrative claims databases in conducting clinical real-world evidence studies in multiple sclerosis. Curr Med Res Opin 2015;31:1029-39
   PubMed Web of Science ®Google Scholar
• US Bureau of Labor Statistics. Consumer Price Index (CPI) for medical care. Available at: http://data.bls.gov [Last accessed 14 August 2014]
   Google Scholar
• Hess LM, Raebel MA, Conner DA, et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40:1280-8
   PubMed Web of Science ®Google Scholar
• Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-57
   PubMed Web of Science ®Google Scholar
• Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ 2010;13:618-25
   PubMedGoogle Scholar
• Amato MP. Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents. Expert Opin Pharmacother 2004;5:2115-26
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006;66:1696-702
   PubMed Web of Science ®Google Scholar
• Rotstein Z, Hazan R, Barak Y, et al. Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis. Autoimmun Rev 2006;5:511-16
   PubMed Web of Science ®Google Scholar
• Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-25
   PubMed Web of Science ®Google Scholar
• Minagara A, Murray TJ, Investigators PS. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF. Curr Med Res Opin 2008;24:1049-55
   PubMed Web of Science ®Google Scholar
• Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Preference and Adherence 2010;4:1-9
   PubMed Web of Science ®Google Scholar
• Reynolds MW, Stephen R, Seaman C, et al. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. J Med Econ 2010;13:90-8
   PubMedGoogle Scholar
• Evans C, Kingwell E, Zhu F, et al. Hospital admissions and MS: temporal trends and patient characteristics. Am J Manag Care 2012;18:735-42
   PubMed Web of Science ®Google Scholar
• Marrie RA, Elliott L, Marriott J, et al. Dramatically changing rates and reasons for hospitalization in multiple sclerosis. Neurology 2014;83:929-37
   PubMed Web of Science ®Google Scholar
• Nusrat S, Levinthal D, Bielefeldt K. Hospitalization rates and discharge status in multiple sclerosis. Mult Scler Int 2013;2013:436929
   PubMedGoogle Scholar
• Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a for relapsing–remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014;13:657-65
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819-28
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 2014;20:705-16
   PubMed Web of Science ®Google Scholar